Hypertension
📧 Sign up to get email alerts when something new happens for Hypertension.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2023-02-13FDA Approved: HYDRALAZINE HYDROCHLORIDE — Original Application (Eugia US LLC)
FDA approved Hydralazine hydrochloride as an original-application generic (ANDA) from Eugia US LLC.
-
FDA approval · 2023-02-06FDA Approved: NICARDIPINE HYDROCHLORIDE — Supplemental Application (Lifestar Pharma LLC)
FDA approves a supplemental application for nicardipine hydrochloride (generic) submitted by Lifestar Pharma LLC.
-
FDA approval · 2023-02-01FDA Approved: CATAPRES-TTS-1 — Supplemental Application (Technomed Inc.)
FDA approved a supplemental application for CATAPRES-TTS-1 (clonidine transdermal system) by Technomed Inc.
-
FDA approval · 2023-01-27FDA Approved: CAPTOPRIL — Original Application (AiPing Pharmaceutical, Inc.)
The FDA approved AiPing Pharmaceutical’s Original Application for CAPTOPRIL (captopril), a generic ACE inhibitor. The approval supports indi…
-
CLINICAL_TRIALS trial_result · 2023-01-18Clinical Trial Update: A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx [Phase 2]
Phase 2 trial assessing safety, tolerability and efficacy of IONIS-AGT-LRx in hypertension has completed; results posted in 2023.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-01-18FDA Approved: OLMESARTAN MEDOXOMIL — Original Application (Novadoz Pharmaceuticals LLC)
FDA approved the original application for Olmesartan Medoxomil, a generic version of the hypertension medication, manufactured by Novadoz Ph…
-
CLINICAL_TRIALS trial_result · 2023-01-17Clinical Trial Update: Randomized Study of Extended Treatment With Firibastat in Treatment-Resistant Hypertension (REFRESH) [Phase 3]
Phase 3 randomized study on extended Firibastat treatment in treatment-resistant hypertension has been terminated.
-
CLINICAL_TRIALS trial_result · 2023-01-11Clinical Trial Update: Precision Treatment With Angiotensin Converting Enzyme Inhibitor [Phase 4]
Phase 4 clinical trial update evaluating precision treatment with an ACE inhibitor in hypertension; study completed.
-
CLINICAL_TRIALS trial_result · 2023-01-10Clinical Trial Update: Spermidine Anti-Hypertension Study [Phase 3]
Phase 3 clinical trial update for a spermidine-based treatment targeting hypertension.
-
CLINICAL_TRIALS trial_result · 2023-01-06Clinical Trial Update: A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor Administered Subcutaneously to Hypertensive Participants With Controlled Blood Pressure [Phase 2]
Phase 2 trial assessing safety, tolerability, and efficacy of IONIS-AGT-LRx in adults with mild hypertension has completed with posted resul…
-
CLINICAL_TRIALS trial_result · 2023-01-04Clinical Trial Update: Olive Leaf Extracts in the Control of Cardiovascular Risk [Phase 2, Phase 3]
Phase 2 and Phase 3 trials evaluating olive leaf extracts for cardiovascular risk management in type 2 diabetes and hypertension.
-
CLINICAL_TRIALS trial_result · 2022-12-30Clinical Trial Update: Long-term Ambrisentan Extension Study for Pediatric Patients Who Participated in AMB112529 [Phase 2]
Phase 2 pediatric long-term extension study of ambrisentan for hypertension/pulmonary hypertension completed; results posted.
-
FDA approval · 2022-12-30FDA Approved: PRAZOSIN HYDROCHLORIDE — Original Application (Lifestar Pharma LLC)
FDA approved an original application for prazosin hydrochloride as a generic drug manufactured by Lifestar Pharma LLC.
-
FDA approval · 2022-12-29FDA Approved: OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE — Supplemental Application (Solco Healthcare US, LLC)
The FDA approved a supplemental application for the generic fixed-dose combination of olmesartan medoxomil and hydrochlorothiazide from Solc…
-
CLINICAL_TRIALS trial_result · 2022-12-29Clinical Trial Update: Insomnia Prevalence and Treatment Impact on Systemic Hypertension [Phase 4]
Phase 4 clinical trial investigating insomnia prevalence and its impact on systemic hypertension has been terminated.
-
FDA approval · 2022-12-19FDA Approved: MICARDIS — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
The FDA approved a supplemental application for MICARDIS (telmisartan) submitted by Boehringer Ingelheim Pharmaceuticals, expanding the labe…
-
FDA approval · 2022-12-19FDA Approved: SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE — Supplemental Application (Prasco Laboratories)
FDA approves a supplemental application for the combination product spironolactone and hydrochlorothiazide, manufactured by Prasco Laborator…
-
FDA approval · 2022-12-19FDA Approved: MICARDIS HCT — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
The FDA approved a supplemental application for MICARDIS HCT (telmisartan and hydrochlorothiazide) from Boehringer Ingelheim Pharmaceuticals…
-
FDA approval · 2022-12-16FDA Approved: NICARDIPINE HYDROCHLORIDE — Original Application (Glenmark Pharmaceuticals Inc., USA)
FDA approved Glenmark's nicardipine hydrochloride generic under an original ANDA, enabling its marketing for indicated uses.
-
FDA approval · 2022-12-16FDA Approved: FUROSEMIDE — Original Application (Lifestar Pharma LLC)
FDA approved Lifestar Pharma LLC's original application for furosemide, authorizing the generic version of the diuretic for its labeled indi…
-
CLINICAL_TRIALS trial_result · 2022-12-15Clinical Trial Update: A Study of the Effect of Topical Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism [Phase 4]
Phase 4 trial evaluating the effect of topical testosterone replacement therapy on blood pressure in adult males with hypogonadism; results …
-
CLINICAL_TRIALS trial_result · 2022-12-12Clinical Trial Update: A Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of DWC202206 and DWC202207 in Patients With Concomitant Hypertension and Hyperlipidemia [Phase 3]
A Phase 3 clinical trial evaluating the efficacy and safety of co-administration of DWC202206 and DWC202207 in adults with both hypertension…
-
CLINICAL_TRIALS trial_result · 2022-12-09Clinical Trial Update: Chymase Angiotensin-(1-12) Axis In Hypertensive Disease [Phase 4]
Phase 4 clinical trial update related to the chymase Angiotensin-(1-12) axis in hypertensive disease.
-
CLINICAL_TRIALS trial_result · 2022-12-07Clinical Trial Update: Study on Human Mass Balance of SPH3127 Tablets [Phase 1, Phase 2]
Phase 1/2 study evaluating human mass balance of SPH3127 tablets for hypertension has completed.
-
FDA approval · 2022-12-02FDA Approved: OLMESARTAN MEDOXOMIL — Original Application (Solco Healthcare US, LLC.)
The FDA approved the original application for olmesartan medoxomil from Solco Healthcare US, LLC., granting a generic option for treating hy…